Critical illness polyneuropathy and myopathy: A systematic review

Neural Regeneration Research

Volumn 9, Issue 1, 2014, Pages 101-110

  Zhou, Chunkui ^a   Wu, Limin ^a,b   Ni, Fengming ^a   Ji, Wei ^c   Wu, Jiang ^a   Zhang, Hongliang ^a  

^a JILIN UNIVERSITY   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

^c People's Hospital of Jilin Province   (China)

Author keywords

Critical illness myopathy; Critical illness polyneuropathy; Guillain Barr ; Intensive care unit; Multiple organ failure; Nerve regeneration; Neural regeneration; Neurodegenerative diseases; NSFC grant; Sepsis; Syndrome

Indexed keywords

IMMUNOGLOBULIN;

AMINO ACID DEFICIENCY; APOPTOSIS; ARTICLE; ARTIFICIAL VENTILATION; DIET THERAPY; ENDOCRINE DISEASE; EXERCISE; EXTRAVASATION; GUILLAIN BARRE SYNDROME; HORMONAL THERAPY; HUMAN; HYPERGLYCEMIA; LIMB WEAKNESS; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; MYOPATHY; PHYSIOTHERAPY; POLYNEUROPATHY; PROGNOSIS; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VASODILATATION;

EID: 84896309666     PISSN: 16735374     EISSN: 18767958     Source Type: Journal    
DOI: 10.4103/1673-5374.125337     Document Type: Article

References (112)

1. Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve. 2000;23(12):1785-1788.
2. Zochodne DW, Bolton CF, Wells GA, et al. Critical illness polyneuropathy. A complication of sepsis and multiple organ failure. Brain. 1987;110(Pt 4):819-841.
3. Lacomis D. Neuromuscular disorders in critically ill patients: review and update. J Clin Neuromuscul Dis. 2011;12(4):197-218.
4. Bolton CF, Laverty DA, Brown JD, et al. Critically ill polyneuropathy: electrophysiological studies and differentiation from Guillain- Barre syndrome. J Neurol Neurosurg Psychiatry. 1986;49(5): 563-573.
5. Hermans G, De Jonghe B, Bruyninckx F, et al. Clinical review: Critical illness polyneuropathy and myopathy. Crit Care. 2008;12(6):238.
6. Gurjar M, Azim A, Baronia AK, et al. Facial nerve involvement in critical illness polyneuropathy. Indian J Anaesth. 2010;54(5):472-474.
7. Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry. 2008;79(7):838-841.
8. Osler W, The Principles and Practice of Medicine. New York: D. Appleton & Co. 1892.
9. Mertens HG. Disseminated neuropathy following coma. On the differentation of socalled toxic neuropathy. Nervenarzt. 1961; 32(1):71-79.
10. Bolton CF, Gilbert JJ, Hahn AF, et al. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry. 1984;47(11):1223-1231.
11. Lacomis D, Giuliani MJ, Van Cott A, et al. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol. 1996;40(4):645-654.
12. Campellone JV. Clinical approach to neuromuscular weakness in the critically ill patient. J Clin Neuromuscul Dis. 2000;1(3):151-158.
13. Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 2011;10(10):931-941.
14. Bednarik J, Vondracek P, Dusek L, et al. Risk factors for critical illness polyneuromyopathy. J Neurol. 2005;252(3):343-351.
15. Bercker S, Weber-Carstens S, Deja M, et al. Critical illness polyneuropathy and myopathy in patients with acute respiratory distress syndrome. Crit Care Med. 2005;33(4):711-715.
16. Witt NJ, Zochodne DW, Bolton CF, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest. 1991;99(1):176-184.
17. Tennila A, Salmi T, Pettila V, et al. Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med. 2000;26(9):1360-1363.
18. Douglass JA, Tuxen DV, Horne M, et al. Myopathy in severe asthma. Am Rev Respir Dis. 1992;146(2):517-519.
19. Coakley JH, Nagendran K, Yarwood GD, et al. Patterns of neurophysiological abnormality in prolonged critical illness. Intensive Care Med. 1998;24(8):801-807.
20. Koch S, Spuler S, Deja M, et al. Critical illness myopathy is frequent: accompanying neuropathy protracts ICU discharge. J Neurol Neurosurg Psychiatry. 2011;82(3):287-293.
21. Khan J, Harrison TB, Rich MM, et al. Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology. 2006;67(8):1421-1425.
22. Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol. 2001;248(11):929-934.
23. De Letter MA, Schmitz PI, Visser LH, et al. Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med. 2001;29(12):2281-2286.
24. Zink W, Kollmar R, Schwab S. Critical illness polyneuropathy and myopathy in the intensive care unit. Nat Rev Neurol. 2009;5(7): 372-379.
25. Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology. 2005;64(8):1348-1353.
26. Gheith O, Al Otaibi T, Abdelhalim M, et al. Successful management of critical illness polyneuropathy and myopathy in renal transplant recipients. Exp Clin Transplant. 2012;10(1):62-66.
27. Wilmshurst PT, Treacher DF, Lantos PL, et al. Critical illness poly- neuropathy following severe hyperpyrexia. QJM. 1995;88(5): 351-355.
28. Garnacho-Montero J, Madrazo-Osuna J, Garcia-Garmendia JL, et al. Critical illness polyneuropathy: risk factors and clinical consequences. A cohort study in septic patients. Intensive Care Med. 2001;27(8):1288-1296.
29. Dussoix P, Chevrolet JC, Cox J, et al. Secondary neuromyopathies in a resuscitation unit. Reanimation Urgences. 1993;2(1):247-258.
30. Anastasopoulos D, Kefaliakos A, Michalopoulos A. Is plasma calcium concentration implicated in the development of critical illness polyneuropathy and myopathy? Critical Care. 2011;15(5):R247.
31. Hermans G, De Jonghe B, Bruyninckx F, et al. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev. 2009;21(1):CD006832.
32. Amaya-Villar R, Garnacho-Montero J, Garcia-Garmendi JL, et al. Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2005;31(1):157-161.
33. Boles JM, Bion J, Connors A, et al. Weaning from mechanical ventilation. Eur Respir J. 2007;29(5):1033-1056.
34. Lacomis DJ. Neuromuscular disorders in critically ill patients: review and update. J Clin Neuromuscul Dis. 2011;12(4):197-218.
35. Friedrich O, Hund E, Weber C, et al. Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol. 2004;251(1): 53-65.
36. Friedrich O. Critical illness myopathy: sepsis-mediated failure of the peripheral nervous system. Eur J Anaesthesiol. 2008;42(1):73-82.
37. Fenzi F, Latronico N, Refatti N, et al. Enhanced expression of e-selectin on the vascular endothelium of peripheral nerve in critically ill patients with neuromuscular disorders. Acta Neuropathol. 2003;106(1):75-82.
38. Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Curr Opin Crit Care. 2005;11(2):126-132.
39. Gamrin L, Andersson K, Hultman E, et al. Longitudinal changes of biochemical parameters in muscle during critical illness. Metabolism. 1997;46(7):756-762.
40. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve. 1997;20(3):316-322.
41. Tiao G, Hobler S, Wang JJ, et al. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle. J Clin Invest. 1997;99(2):163-168.
42. Klaude M, Fredriksson K, Tjader I, et al. Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin Sci (Lond). 2007;112(9):499-506.
43. Di Giovanni S, Molon A, Broccolini A, et al. Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol. 2004;55(2):195-206.
44. Di Giovanni S, Mirabella M, D'Amico A, et al. Apoptotic features accompany acute quadriplegic myopathy. Neurology. 2000;55(6): 854-858.
45. Wagenmakers AJ. Muscle function in critically ill patients. Clin Nutr. 2001;20(5):451-454.
46. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve. 2005;32(2):140-163.
47. Rich MM, Pinter MJ. Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol. 2003;547(Pt 2):555-566.
48. Filatov GN, Rich MM. Hyperpolarized shifts in the voltage dependence of fast inactivation of Nav1.4 and Nav1.5 in a rat model of critical illness myopathy. J Physiol. 2004;559(Pt 3):813-820.
49. Rossignol B, Gueret G, Pennec JP, et al. Effects of chronic sepsis on the voltage-gated sodium channel in isolated rat muscle fibers. Crit Care Med. 2007;35(2):351-357.
50. Allen DC, Arunachalam R, Mills KR. Critical illness myopathy: further evidence from muscle-fiber excitability studies of an acquired channelopathy. Muscle Nerve. 2008;37(1):14-22.
51. Haeseler G, Foadi N, Wiegand E, et al. Endotoxin reduces availability of voltage-gated human skeletal muscle sodium channels at depolarized membrane potentials. Crit Care Med. 2008;36:1239-1247.
52. Z'Graggen WJ, Lin CS, Howard RS, et al. Nerve excitability changes in critical illness polyneuropathy. Brain. 2006;129(Pt 9):2461-2470.
53. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360(3928):219-223.
54. Druschky A, Herkert M, Radespiel-Troger M, et al. Critical illness polyneuropathy: Clinical findings and cell culture assay of neurotoxicity assessed by a prospective study. Intensive Care Med. 2001;27(4):686-693.
55. Latronico N, Guarneri B. Critical illness myopathy and neuropathy. Minerva Anestesiol. 2008;74(6):319-323.
56. De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002;288(22):2859-2867.
57. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet. 1996;347(1):1579-1582.
58. Bednarik J, Lukas Z, Vondracek P. Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Intensive Care Med. 2003;29(9):1505-1514.
59. Cankayali I, Dogan YH, Solak I, et al. Neuromuscular deterioration in the early stage of sepsis in rats. Crit Care. 2007;11(1):R1.
60. Stibler H, Edstrom L, Ahlbeck K, et al. Electrophoretic determination of the myosin/actin ratio in the diagnosis of critical illness myopathy. Intensive Care Med. 2003;29(9):1515-1527.
61. Latronico N, Bertolini G, Guarneri B, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care. 2007;11(1):R11.
62. Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. J Neurol Neurosurg Psychiatry. 2008;79(7):838-841.
63. Baum P, Bercker S, Villmann T, et al. Critical illness myopathy and neuropathy (CRIMYN). Electroneurographic classification. Nervenarzt. 2011;82(4):468-474.
64. Rich MM, Raps EC, Bird SJ. Distinction between acute myopathy syndrome and critical illness polyneuropathy. Mayo Clin Proc. 1995;70(2):198-200.
65. Trojaborg W. Electrophysiologic techniques in critical illness-associated weakness. J Neurol Sci. 2006;242(1-2):83-85.
66. Rich MM, Bird SJ, Raps EC, et al. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve. 1997;20(6):665-673.
67. Lefaucheur JP, Nordine T, Rodriguez P, et al. Origin of ICU acquired paresis determined by direct muscle stimulation. J Neurol Neurosurg Psychiatry. 2006;77(4):500-506.
68. Pandit L, Agrawal A. Neuromuscular disorders in critical illness. Clin Neurol Neurosurg. 2006;108(7):621-627.
69. Barohn RJ, Jackson CE, Rogers SJ, et al. Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids. Muscle Nerve. 1994;17(6):647-654.
70. De Letter MA, van Doorn PA, Savelkoul HF, et al. Critical illness polyneuropathy and myopathy (CiPNM): evidence for local immune activation by cytokine expression in the muscle tissue. J Neuroimmunol. 2000;106(1-2):206-213.
71. Stevens RD, Marshall SA, Cornblath DR, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37(10):S299-308.
72. Wiles CM. Neurological complications of severe illness and prolonged mechanical ventilation. Thorax. 1996;51(Suppl 2):S40-44.
73. Wieske L, Harmsen RE, Schultz MJ, et al. Is critical illness neuromyopathy and duration of mechanical ventilation decreased by strict glucose control? Neurocrit Care. 2011;14(3):475-481.
74. Tzanis G, Vasileiadis I, Zervakis D, et al. Maximum inspiratory pressure, a surrogate parameter for the assessment of ICU-acquired weakness. BMC Anesthesiol. 2011;11(1):14.
75. Rooney KA, Thomas NJ. Severe pulmonary hypertension associated with the acute motor sensory axonal neuropathy subtype of Guillain- Barre syndrome. Pediatr Crit Care Med. 2010;11(1):e16-19.
76. Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain- Barre syndrome. J Neuroimmunol. 1999;100(1-2):74-97.
77. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol. 2008; 7(10):939-950.
78. Latronico N, Rasulo FA, Recupero D, et al. Acute quadriplegia with delayed onset and rapid recovery. Case report. J Neurosurg. 1998; 88(4):769-772.
79. Van der Meche FG, van Doorn PA. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol. 1995; 37(suppl 1):S14-31.
80. Algahtani H, Moulin DE, Bolton CF, et al. Guillain-Barre syndrome following cardiac surgery. Difficult diagnosis in the intensive care unit. Neurosciences (Riyadh). 2009;14(4):374-378.
81. Green DM. Weakness in the ICU: Guillain-Barre syndrome, myasthenia gravis, and critical illness polyneuropathy/myopathy. Neurologist. 2005;11(6):338-347.
82. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003;29(9):1417-1425.
83. Yu YM, Ryan CM, Fei ZW, et al. Plasma L-5-oxoproline kinetics and whole blood glutathione synthesis rates in severely burned adult humans. Am J Physiol Endocrinol Metab. 2002;282(2):E247-258.
84. Schols AM, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Resp Crit Care Med. 1995;152(4 Pt 1):1268-1274.
85. Morris PE, Goad A, Thompson C, et al. Early intensive care unit mobility therapy in the treatment of acute respiratory failure. Crit Care Med. 2008;36(8):2238-2243.
86. Hermans G, Wilmer A, Meersseman W, et al. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Resp Crit Care Med. 2007;175(5):480-489.
87. Hansen TK, Thiel S, Wouters PJ, et al. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88(3):1082-1088.
88. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest. 2005;115(8):2277-2286.
89. Ishii DN, Lupien SB. Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J Neurosci Res. 1995;40(1):138-144.
90. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283-1297.
91. Hermans G, Schrooten M, Van Damme P, et al. Benefits of intensive insulin therapy on neuromuscular complications in routine daily critical care practice: a retrospective study. Crit Care. 2009; 13(1):R5.
92. Rochester CL. Rehabilitation in the intensive care unit. Semin Respir and Crit Care Med. 2009;30(6):656-669.
93. Needham DM. Mobilizing patients in the intensive care unit: improving neuromuscular weakness and physical function. JAMA. 2008;300(14):1685-1690.
94. Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009; 373(9678):1874-1882.
95. Karatzanos E, Gerovasili V, Zervakis D, et al. Electrical muscle stimulation: an effective form of exercise and early mobilization to preserve muscle strength in critically ill patients. Crit Care Res Prac. 2012;2012(1):432752.
96. Nuhr MJ, Pette D, Berger R, et al. Beneficial effects of chronic low-frequency stimulation of thigh muscles in patients with advanced chronic heart failure. Eur Heart J. 2004;25(2):136-143.
97. Vivodtzev I, Pepin JL, Vottero G, et al. Improvement in quadricepsstrenght and dyspnea in daily tasks after 1 month of electrical stimulation in severely deconditioned and malnourished COPD. Chest. 2006;129(6):1540-1548.
98. Sillen MJ, Speksnijder CM, Eterman RM, et al. Effects of neuromuscular electrical stimulation of muscles of ambulation in patients with chronic heart failure or COPD: a systematic review of the English-language literature. Chest. 2009;136(1):44-61.
99. Gruther W, Kainberger F, Fialka-Moser V, et al. Effects of neuromuscular electrical stimulation on muscle layer thickness of knee extensor muscles in intensive care unit patients: a pilot study. J Rehabil Med. 2010;42(6):593-597.
100. Strasser EM, Stattner S, Karner J, et al. Neuromuscular electrical stimulation reduces skeletal muscle protein degradation and stimulates insulin-like growth factors in an age- and current-dependent manner: a randomized, controlled clinical trial in major abdominal surgical patients. Ann Surg. 2009;249():738-743.
101. Bouletreau P, Patricot MC, Saudin F, et al. Effects of intermittent electrical stimulations on muscle catabolism in intensive care patients. JPEN J Parenter Enteral Nutr. 1987;11(6):552-555.
102. Routsi C, Gerovasili V, Vasileiadis I, et al. Electrical muscle stimulation prevents critical illness polyneuromyopathy: a randomized parallel intervention trial. Crit Care. 2010;14(2):R74.
103. Pattanshetty RB, Gaude GS. Critical illness myopathy and polyneuropathy - A challenge for physiotherapists in the intensive care units. Indian J Crit Care Med. 2011;15(2):78-81.
104. Silva A, Maynard K, Cruz M. Effect of motor physical therapy in critically ill patients. Rev Bras Ter Intensiva. 2010;22(1):85-91.
105. Perme C, and Chadrashekhar R. Early mobility and walking program for patients in intensive care units: creating a standard of care. Am Crit Care. 2009;18(1):212-221.
106. Novak P, Vidmar G, Kuret Z, et al. Rehabilitation of critical illness polyneuropathy and myopathy patients: an observational study. Int J Rehabil Res. 2011;34(4):336-342.
107. Kress JP. Clinical trials of early mobilization of critically ill patients. Crit Care Med. 2009;37(10 Suppl):S442-447.
108. Chawla J, Gruener G. Management of critical illness polyneuropathy and myopathy. Neurol Clin. 2010;28(4):961-977.
109. Mohr M, Englisch L, Roth A, et al. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med. 1997;23(11):1144-1149.
110. Latronico N, Rasulo FA. Presentation and management of ICU myopathy and neuropathy. Curr Opin Crit Care. 2010;16(2):123-127.
111. Latronico N, Guarneri B, Alongi S, et al. Acute neuromuscular respiratory failure after ICU discharge. Report of five patients. Intensive Care Med. 1999;25(11):1302-1306.
112. Latronico I, Shehu I, Guarneri B. Use of electrophysiologic testing. Crit Care Med. 2009;37(10 Suppl):S316-320.